SHORT MINI-FUTURE - ELI LILLY & CO | Delayed Deutsche Boerse AG 11:32:46 15/05/2024 pm IST | ||
| 19.08 EUR | -9.66% |
|
| Current month | +8.92% | ||
| 1 month | -3.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 19.08 | -9.66% |
| 14/24/14 | 21.12 | -1.72% |
| 13/24/13 | 21.49 | +3.07% |
| 10/24/10 | 20.85 | +5.09% |
| 09/24/09 | 19.84 | +1.28% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 11:32 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KLL |
| ISIN | DE000VD0KLL2 |
| Date issued | 19/02/2024 |
| Strike | 986.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.66 € |
|---|---|
| Lowest since issue | 17.48 € |
| Spread | 0.04 € |
| Spread % | 0.21% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- Certificat
